{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:26:15Z","timestamp":1790832375884,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["21H00294"],"award-info":[{"award-number":["21H00294"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["22H02576"],"award-info":[{"award-number":["22H02576"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["PEDEMO20G0"],"award-info":[{"award-number":["PEDEMO20G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC #9\/2019"],"award-info":[{"award-number":["FFC #9\/2019"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC #10\/2021"],"award-info":[{"award-number":["FFC #10\/2021"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC#11\/2019"],"award-info":[{"award-number":["FFC#11\/2019"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC#7\/2020"],"award-info":[{"award-number":["FFC#7\/2020"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cystic Fibrosis (CF) is a genetic disease caused by mutations in <jats:italic>CFTR<\/jats:italic> gene expressing the anion selective channel CFTR located at the plasma membrane of different epithelial cells. The most commonly investigated variant causing CF is F508del. This mutation leads to structural defects in the CFTR protein, which are recognized by the endoplasmic reticulum (ER) quality control system. As a result, the protein is retained in the ER and degraded via the ubiquitin\u2013proteasome pathway. Although blocking ubiquitination to stabilize the CFTR protein has long been considered a potential pharmacological approach in CF, progress in this area has been relatively slow. Currently, no compounds targeting this pathway have entered clinical trials for CF. On the other hand, the emergence of Orkambi initially, and notably the subsequent introduction of Trikafta\/Kaftrio, have demonstrated the effectiveness of molecular chaperone-based therapies for patients carrying the F508del variant and even showed efficacy against other variants. These treatments directly target the CFTR variant protein without interfering with cell signaling pathways. This review discusses the limits and potential future of targeting protein ubiquitination in CF.<\/jats:p>","DOI":"10.1007\/s00018-024-05295-z","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T15:00:09Z","timestamp":1718722809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting ubiquitination machinery in cystic fibrosis: Where do we stand?"],"prefix":"10.1007","volume":"81","author":[{"given":"Tsukasa","family":"Okiyoneda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Borgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bosello Travain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-6048","authenticated-orcid":false,"given":"Mauro","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"5295_CR1","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC (2021) Cystic fibrosis. Lancet 397:2195\u20132211. https:\/\/doi.org\/10.1016\/S0140-6736(20)32542-3","journal-title":"Lancet"},{"key":"5295_CR2","unstructured":"CFTR2 Variant List History | CFTR2. https:\/\/cftr2.org\/mutations_history. Accessed 11 Aug 2023"},{"key":"5295_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.E14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit G, Avramescu RG, Chiang AN et al (2016) From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 27:424\u2013433. https:\/\/doi.org\/10.1091\/mbc.E14-04-0935","journal-title":"Mol Biol Cell"},{"key":"5295_CR4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0092-8674(90)90148-8","volume":"63","author":"SH Cheng","year":"1990","unstructured":"Cheng SH, Gregory RJ, Marshall J et al (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63:827\u2013834. https:\/\/doi.org\/10.1016\/0092-8674(90)90148-8","journal-title":"Cell"},{"key":"5295_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0092-8674(95)90240-6","volume":"83","author":"CL Ward","year":"1995","unstructured":"Ward CL, Omura S, Kopito RR (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83:121\u2013127. https:\/\/doi.org\/10.1016\/0092-8674(95)90240-6","journal-title":"Cell"},{"key":"5295_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0092-8674(95)90241-4","volume":"83","author":"TJ Jensen","year":"1995","unstructured":"Jensen TJ, Loo MA, Pind S et al (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83:129\u2013135. https:\/\/doi.org\/10.1016\/0092-8674(95)90241-4","journal-title":"Cell"},{"key":"5295_CR7","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Van Goor","year":"2009","unstructured":"Van Goor F, Hadida S, Grootenhuis PDJ et al (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106:18825\u201318830. https:\/\/doi.org\/10.1073\/pnas.0904709106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5295_CR8","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","volume":"363","author":"FJ Accurso","year":"2010","unstructured":"Accurso FJ, Rowe SM, Clancy JP et al (2010) Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation. N Engl J Med 363:1991\u20132003. https:\/\/doi.org\/10.1056\/NEJMoa0909825","journal-title":"N Engl J Med"},{"key":"5295_CR9","doi-asserted-by":"publisher","first-page":"113195","DOI":"10.1016\/j.ejmech.2021.113195","volume":"213","author":"E Bardin","year":"2021","unstructured":"Bardin E, Pastor A, Semeraro M et al (2021) Modulators of CFTR. Updates on clinical development and future directions. Eur J Med Chem 213:113195. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113195","journal-title":"Eur J Med Chem"},{"key":"5295_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/humu.10041","volume":"19","author":"JL Bobadilla","year":"2002","unstructured":"Bobadilla JL, Macek M, Fine JP, Farrell PM (2002) Cystic fibrosis: a worldwide analysis of CFTR mutations\u2013correlation with incidence data and application to screening. Hum Mutat 19:575\u2013606. https:\/\/doi.org\/10.1002\/humu.10041","journal-title":"Hum Mutat"},{"key":"5295_CR11","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1172\/JCI24898","volume":"115","author":"N Pedemonte","year":"2005","unstructured":"Pedemonte N, Lukacs GL, Du K et al (2005) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115:2564\u20132571. https:\/\/doi.org\/10.1172\/JCI24898","journal-title":"J Clin Invest"},{"key":"5295_CR12","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.jcf.2017.08.013","volume":"17","author":"H Li","year":"2018","unstructured":"Li H, Pesce E, Sheppard DN et al (2018) Therapeutic approaches to CFTR dysfunction: From discovery to drug development. J Cyst Fibros 17:S14\u2013S21. https:\/\/doi.org\/10.1016\/j.jcf.2017.08.013","journal-title":"J Cyst Fibros"},{"key":"5295_CR13","doi-asserted-by":"publisher","first-page":"e00152","DOI":"10.1002\/prp2.152","volume":"3","author":"CM Farinha","year":"2015","unstructured":"Farinha CM, Sousa M, Canato S et al (2015) Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect 3:e00152. https:\/\/doi.org\/10.1002\/prp2.152","journal-title":"Pharmacol Res Perspect"},{"key":"5295_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","volume":"185","author":"K Fiedorczuk","year":"2022","unstructured":"Fiedorczuk K, Chen J (2022) Mechanism of CFTR correction by type I folding correctors. Cell 185:158-168.e11. https:\/\/doi.org\/10.1016\/j.cell.2021.12.009","journal-title":"Cell"},{"key":"5295_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1126\/science.ade2216","volume":"378","author":"K Fiedorczuk","year":"2022","unstructured":"Fiedorczuk K, Chen J (2022) Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators. Science 378:284\u2013290. https:\/\/doi.org\/10.1126\/science.ade2216","journal-title":"Science"},{"key":"5295_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW et al (2015) Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:220\u2013231. https:\/\/doi.org\/10.1056\/NEJMoa1409547","journal-title":"N Engl J Med"},{"key":"5295_CR17","doi-asserted-by":"publisher","first-page":"204062232210981","DOI":"10.1177\/20406223221098136","volume":"13","author":"J Roda","year":"2022","unstructured":"Roda J, Pinto-Silva C, Silva IAI et al (2022) New drugs in cystic fibrosis: what has changed in the last decade? Therap Adv Chronic Dis 13:20406223221098136. https:\/\/doi.org\/10.1177\/20406223221098136","journal-title":"Therap Adv Chronic Dis"},{"key":"5295_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1513\/AnnalsATS.202002-144OC","volume":"18","author":"SD Sagel","year":"2021","unstructured":"Sagel SD, Khan U, Heltshe SL et al (2021) Clinical Effectiveness of Lumacaftor\/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial Annals ATS 18:75\u201383. https:\/\/doi.org\/10.1513\/AnnalsATS.202002-144OC","journal-title":"A Clinical Trial Annals ATS"},{"key":"5295_CR19","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2019","unstructured":"Lopes-Pacheco M (2019) CFTR Modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 10:1662. https:\/\/doi.org\/10.3389\/fphar.2019.01662","journal-title":"Front Pharmacol"},{"key":"5295_CR20","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P et al (2019) Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med 381:1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","journal-title":"N Engl J Med"},{"key":"5295_CR21","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","volume":"402","author":"JL Taylor-Cousar","year":"2023","unstructured":"Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG (2023) CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet 402:1171\u20131184. https:\/\/doi.org\/10.1016\/S0140-6736(23)01609-4","journal-title":"Lancet"},{"key":"5295_CR22","doi-asserted-by":"publisher","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","volume":"62","author":"E Dreano","year":"2023","unstructured":"Dreano E, Burgel PR, Hatton A et al (2023) Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription. Eur Respir J 62:2300110. https:\/\/doi.org\/10.1183\/13993003.00110-2023","journal-title":"Eur Respir J"},{"key":"5295_CR23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","volume":"20","author":"G Veit","year":"2021","unstructured":"Veit G, Vaccarin C, Lukacs GL (2021) Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR. J Cyst Fibros 20:895\u2013898. https:\/\/doi.org\/10.1016\/j.jcf.2021.03.011","journal-title":"J Cyst Fibros"},{"key":"5295_CR24","doi-asserted-by":"publisher","first-page":"210112","DOI":"10.1183\/20734735.0112-2021","volume":"17","author":"DH Tewkesbury","year":"2021","unstructured":"Tewkesbury DH, Robey RC, Barry PJ (2021) Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy. Breathe (Sheff) 17:210112. https:\/\/doi.org\/10.1183\/20734735.0112-2021","journal-title":"Breathe (Sheff)"},{"key":"5295_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/liv.14839","volume":"41","author":"A Ben Saad","year":"2021","unstructured":"Ben Saad A, Vauthier V, T\u00f3th \u00c1 et al (2021) Effect of CFTR correctors on the traffic and the function of intracellularly retained ABCB4 variants. Liver Int 41:1344\u20131357. https:\/\/doi.org\/10.1111\/liv.14839","journal-title":"Liver Int"},{"key":"5295_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/hmg\/ddab260","volume":"31","author":"M Scano","year":"2022","unstructured":"Scano M, Benetollo A, Nogara L et al (2022) CFTR corrector C17 is effective in muscular dystrophy, in vivo proof of concept in LGMDR3. Hum Mol Genet 31:499\u2013509. https:\/\/doi.org\/10.1093\/hmg\/ddab260","journal-title":"Hum Mol Genet"},{"key":"5295_CR27","doi-asserted-by":"publisher","first-page":"C866","DOI":"10.1152\/ajpcell.00404.2009","volume":"298","author":"N Pedemonte","year":"2010","unstructured":"Pedemonte N, Tomati V, Sondo E, Galietta LJV (2010) Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol 298:C866-874. https:\/\/doi.org\/10.1152\/ajpcell.00404.2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"5295_CR28","doi-asserted-by":"publisher","first-page":"5212","DOI":"10.1021\/acs.jmedchem.1c01897","volume":"65","author":"I Brusa","year":"2022","unstructured":"Brusa I, Sondo E, Falchi F et al (2022) Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives. J Med Chem 65:5212\u20135243. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01897","journal-title":"J Med Chem"},{"key":"5295_CR29","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1042\/BST20221468","volume":"51","author":"S Taniguchi","year":"2023","unstructured":"Taniguchi S, Fukuda R, Okiyoneda T (2023) The multiple ubiquitination mechanisms in CFTR peripheral quality control. Biochem Soc Trans 51:1297\u20131306. https:\/\/doi.org\/10.1042\/BST20221468","journal-title":"Biochem Soc Trans"},{"key":"5295_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1385\/JMN:23:1-2:041","volume":"23","author":"MD Amaral","year":"2004","unstructured":"Amaral MD (2004) CFTR and chaperones: processing and degradation. J Mol Neurosci 23:41\u201348. https:\/\/doi.org\/10.1385\/JMN:23:1-2:041","journal-title":"J Mol Neurosci"},{"issue":"Suppl 1","key":"5295_CR31","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jcf.2019.10.017","volume":"19","author":"MD Amaral","year":"2020","unstructured":"Amaral MD, Hutt DM, Tomati V et al (2020) CFTR processing, trafficking and interactions. J Cyst Fibros 19(Suppl 1):S33\u2013S36. https:\/\/doi.org\/10.1016\/j.jcf.2019.10.017","journal-title":"J Cyst Fibros"},{"key":"5295_CR32","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1083\/jcb.200410065","volume":"167","author":"JM Younger","year":"2004","unstructured":"Younger JM, Ren H-Y, Chen L et al (2004) A foldable CFTR{Delta}F508 biogenic intermediate accumulates upon inhibition of the Hsc70-CHIP E3 ubiquitin ligase. J Cell Biol 167:1075\u20131085. https:\/\/doi.org\/10.1083\/jcb.200410065","journal-title":"J Cell Biol"},{"key":"5295_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/35050509","volume":"3","author":"GC Meacham","year":"2001","unstructured":"Meacham GC, Patterson C, Zhang W et al (2001) The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol 3:100\u2013105. https:\/\/doi.org\/10.1038\/35050509","journal-title":"Nat Cell Biol"},{"key":"5295_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/358761a0","volume":"358","author":"GM Denning","year":"1992","unstructured":"Denning GM, Anderson MP, Amara JF et al (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358:761\u2013764. https:\/\/doi.org\/10.1038\/358761a0","journal-title":"Nature"},{"key":"5295_CR35","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E23-08-0336","author":"C Riepe","year":"2023","unstructured":"Riepe C, W\u0105chalska M, Deol KK et al (2023) Small molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states. Mol Biol Cell. https:\/\/doi.org\/10.1091\/mbc.E23-08-0336","journal-title":"Mol Biol Cell"},{"key":"5295_CR36","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1083\/jcb.200312018","volume":"164","author":"M Sharma","year":"2004","unstructured":"Sharma M, Pampinella F, Nemes C et al (2004) Misfolding diverts CFTR from recycling to degradation\u202f: quality control at early endosomes. J Cell Biol 164:923\u2013933. https:\/\/doi.org\/10.1083\/jcb.200312018","journal-title":"J Cell Biol"},{"key":"5295_CR37","doi-asserted-by":"publisher","first-page":"C166","DOI":"10.1152\/ajpcell.2001.280.1.C166","volume":"280","author":"GD Heda","year":"2001","unstructured":"Heda GD, Tanwani M, Marino CR (2001) The \u0394F508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am J Physiol Cell Physiol 280:C166\u2013C174. https:\/\/doi.org\/10.1152\/ajpcell.2001.280.1.C166","journal-title":"Am J Physiol Cell Physiol"},{"key":"5295_CR38","doi-asserted-by":"publisher","first-page":"165611","DOI":"10.1016\/j.bbadis.2019.165611","volume":"1866","author":"C D\u2019Amore","year":"2020","unstructured":"D\u2019Amore C, Borgo C, Bosello-Travain V et al (2020) Diphering the role of protein kinase CK2 in the maturation\/stability of F508del-CFTR. Biochim Biophys Acta Mol Basis Dis 1866:165611. https:\/\/doi.org\/10.1016\/j.bbadis.2019.165611","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"Suppl 1","key":"5295_CR39","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1007\/s004240100652","volume":"443","author":"D Dahan","year":"2001","unstructured":"Dahan D, Evagelidis A, Hanrahan JW et al (2001) Regulation of the CFTR channel by phosphorylation. Pflugers Arch 443(Suppl 1):S92-96. https:\/\/doi.org\/10.1007\/s004240100652","journal-title":"Pflugers Arch"},{"key":"5295_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aan7984","author":"S Pankow","year":"2019","unstructured":"Pankow S, Bamberger C, Yates JR (2019) A posttranslational modification code for CFTR maturation is altered in cystic fibrosis. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.aan7984","journal-title":"Sci Signal"},{"key":"5295_CR41","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1021\/acs.molpharmaceut.7b00928","volume":"15","author":"LA Perkins","year":"2018","unstructured":"Perkins LA, Fisher GW, Naganbabu M et al (2018) High-Content Surface and Total Expression siRNA Kinase Library Screen with VX-809 Treatment Reveals Kinase Targets that Enhance F508del-CFTR Rescue. Mol Pharmaceutics 15:759\u2013767. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00928","journal-title":"Mol Pharmaceutics"},{"key":"5295_CR42","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1111\/febs.12345","volume":"280","author":"MD Amaral","year":"2013","unstructured":"Amaral MD, Farinha CM (2013) Post-translational modifications of CFTR: insight into protein trafficking and cystic fibrosis disease. FEBS J 280:4395\u20134395. https:\/\/doi.org\/10.1111\/febs.12345","journal-title":"FEBS J"},{"key":"5295_CR43","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.3390\/ijms21144844","volume":"21","author":"F Degrugillier","year":"2020","unstructured":"Degrugillier F, Aissat A, Pruli\u00e8re-Escabasse V et al (2020) Phosphorylation of the Chaperone-Like HspB5 Rescues Trafficking and Function of F508del-CFTR. Int J Mol Sci 21:4844. https:\/\/doi.org\/10.3390\/ijms21144844","journal-title":"Int J Mol Sci"},{"key":"5295_CR44","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1091\/mbc.e11-08-0662","volume":"23","author":"X Liang","year":"2012","unstructured":"Liang X, Da Paula AC, Boz\u00f3ky Z et al (2012) Phosphorylation-dependent 14\u20133-3 protein interactions regulate CFTR biogenesis. MBoC 23:996\u20131009. https:\/\/doi.org\/10.1091\/mbc.e11-08-0662","journal-title":"MBoC"},{"key":"5295_CR45","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2174\/1389450116666150531152236","volume":"16","author":"A Ahner","year":"2015","unstructured":"Ahner A, Frizzell RA (2015) SUMOylation Modulates CFTR Biogenesis: Is the Pathway Druggable? Curr Drug Targets 16:965\u2013975. https:\/\/doi.org\/10.2174\/1389450116666150531152236","journal-title":"Curr Drug Targets"},{"key":"5295_CR46","doi-asserted-by":"publisher","first-page":"9612","DOI":"10.3390\/ijms23179612","volume":"23","author":"C D\u2019Amore","year":"2022","unstructured":"D\u2019Amore C, Borgo C, Bosello Travain V, Salvi M (2022) KDM2A and KDM3B as Potential Targets for the Rescue of F508del-CFTR. Int J Mol Sci 23:9612. https:\/\/doi.org\/10.3390\/ijms23179612","journal-title":"Int J Mol Sci"},{"key":"5295_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2018.00029","author":"AJ George","year":"2018","unstructured":"George AJ, Hoffiz YC, Charles AJ et al (2018) A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2018.00029","journal-title":"Front Genet"},{"key":"5295_CR48","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.cell.2006.06.041","volume":"126","author":"JM Younger","year":"2006","unstructured":"Younger JM, Chen L, Ren H-Y et al (2006) Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. Cell 126:571\u2013582. https:\/\/doi.org\/10.1016\/j.cell.2006.06.041","journal-title":"Cell"},{"key":"5295_CR49","doi-asserted-by":"publisher","first-page":"12138","DOI":"10.1038\/srep12138","volume":"5","author":"V Tomati","year":"2015","unstructured":"Tomati V, Sondo E, Armirotti A et al (2015) Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation. Sci Rep 5:12138. https:\/\/doi.org\/10.1038\/srep12138","journal-title":"Sci Rep"},{"key":"5295_CR50","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.chembiol.2018.04.010","volume":"25","author":"E Sondo","year":"2018","unstructured":"Sondo E, Falchi F, Caci E et al (2018) Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia. Cell Chem Biol 25:891-905.e8. https:\/\/doi.org\/10.1016\/j.chembiol.2018.04.010","journal-title":"Cell Chem Biol"},{"key":"5295_CR51","doi-asserted-by":"publisher","first-page":"9797","DOI":"10.1021\/acs.jmedchem.3c00608","volume":"66","author":"I Brusa","year":"2023","unstructured":"Brusa I, Sondo E, Pesce E et al (2023) Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5. J Med Chem 66:9797\u20139822. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00608","journal-title":"J Med Chem"},{"key":"5295_CR52","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E22-06-0233","author":"J Ruan","year":"2022","unstructured":"Ruan J, Liang D, Yan W et al (2022) A small-molecule inhibitor and degrader of the RNF5 ubiquitin ligase. Mol Biol Cell. https:\/\/doi.org\/10.1091\/mbc.E22-06-0233","journal-title":"Mol Biol Cell"},{"key":"5295_CR53","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nature00890","volume":"418","author":"Y Yoshida","year":"2002","unstructured":"Yoshida Y, Chiba T, Tokunaga F et al (2002) E3 ubiquitin ligase that recognizes sugar chains. Nature 418:438\u2013442. https:\/\/doi.org\/10.1038\/nature00890","journal-title":"Nature"},{"key":"5295_CR54","doi-asserted-by":"publisher","first-page":"25489","DOI":"10.1074\/jbc.M116.754283","volume":"291","author":"S Ramachandran","year":"2016","unstructured":"Ramachandran S, Osterhaus SR, Parekh KR et al (2016) SYVN1, NEDD8, and FBXO2 Proteins Regulate \u0394F508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitin-mediated Proteasomal Degradation. J Biol Chem 291:25489\u201325504. https:\/\/doi.org\/10.1074\/jbc.M116.754283","journal-title":"J Biol Chem"},{"key":"5295_CR55","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1091\/mbc.e04-01-0024","volume":"15","author":"A Gnann","year":"2004","unstructured":"Gnann A, Riordan JR, Wolf DH (2004) Cystic fibrosis transmembrane conductance regulator degradation depends on the lectins Htm1p\/EDEM and the Cdc48 protein complex in yeast. Mol Biol Cell 15:4125\u20134135. https:\/\/doi.org\/10.1091\/mbc.e04-01-0024","journal-title":"Mol Biol Cell"},{"key":"5295_CR56","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1091\/mbc.E07-06-0601","volume":"19","author":"D Morito","year":"2008","unstructured":"Morito D, Hirao K, Oda Y et al (2008) Gp78 cooperates with RMA1 in endoplasmic reticulum-associated degradation of CFTR\u0394F508. Mol Biol Cell 19:1328\u20131336. https:\/\/doi.org\/10.1091\/mbc.E07-06-0601","journal-title":"Mol Biol Cell"},{"key":"5295_CR57","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.biocel.2009.10.005","volume":"42","author":"P Ballar","year":"2010","unstructured":"Ballar P, Ors AU, Yang H, Fang S (2010) Differential regulation of CFTRDeltaF508 degradation by ubiquitin ligases gp78 and Hrd1. Int J Biochem Cell Biol 42:167\u2013173. https:\/\/doi.org\/10.1016\/j.biocel.2009.10.005","journal-title":"Int J Biochem Cell Biol"},{"key":"5295_CR58","doi-asserted-by":"publisher","first-page":"25241","DOI":"10.1074\/jbc.M109.035345","volume":"284","author":"H Caohuy","year":"2009","unstructured":"Caohuy H, Jozwik C, Pollard HB (2009) Rescue of DeltaF508-CFTR by the SGK1\/Nedd4-2 signaling pathway. J Biol Chem 284:25241\u201325253. https:\/\/doi.org\/10.1074\/jbc.M109.035345","journal-title":"J Biol Chem"},{"key":"5295_CR59","doi-asserted-by":"publisher","first-page":"L720","DOI":"10.1152\/ajplung.00409.2011","volume":"303","author":"K Koeppen","year":"2012","unstructured":"Koeppen K, Chapline C, Sato JD, Stanton BA (2012) Nedd4-2 does not regulate wt-CFTR in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 303:L720-727. https:\/\/doi.org\/10.1152\/ajplung.00409.2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"5295_CR60","doi-asserted-by":"publisher","first-page":"e0123131","DOI":"10.1371\/journal.pone.0123131","volume":"10","author":"L Fu","year":"2015","unstructured":"Fu L, Rab A, Tang L et al (2015) \u0394F508 CFTR Surface Stability Is Regulated by DAB2 and CHIP-Mediated Ubiquitination in Post-Endocytic Compartments. PLoS ONE 10:e0123131. https:\/\/doi.org\/10.1371\/journal.pone.0123131","journal-title":"PLoS ONE"},{"key":"5295_CR61","doi-asserted-by":"publisher","first-page":"31177","DOI":"10.1074\/jbc.M113.470500","volume":"288","author":"E El Khouri","year":"2013","unstructured":"El Khouri E, Le Pavec G, Toledano MB, Delaunay-Moisan A (2013) RNF185 Is a Novel E3 Ligase of Endoplasmic Reticulum-associated Degradation (ERAD) That Targets Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)*. J Biol Chem 288:31177\u201331191. https:\/\/doi.org\/10.1074\/jbc.M113.470500","journal-title":"J Biol Chem"},{"key":"5295_CR62","unstructured":"Research Square (2019) Degradation of CFTR-F508del By the Ubiquitin E2 Conjugating Enzyme UBE 2L6 and the E3 Ligase RNF19B. https:\/\/www.researchsquare.com. Accessed 12 Apr 2021"},{"key":"5295_CR63","doi-asserted-by":"publisher","DOI":"10.1101\/2023.10.16.562477","author":"Y Kamada","year":"2023","unstructured":"Kamada Y, Ohnishi Y, Nakashima C et al (2023) HERC3 E3 ligase provides an ERAD branch eliminating select membrane proteins. Biorxiv. https:\/\/doi.org\/10.1101\/2023.10.16.562477","journal-title":"Biorxiv"},{"key":"5295_CR64","doi-asserted-by":"publisher","first-page":"27008","DOI":"10.1074\/jbc.M110.139881","volume":"285","author":"S Ye","year":"2010","unstructured":"Ye S, Cihil K, Stolz DB et al (2010) c-Cbl facilitates endocytosis and lysosomal degradation of cystic fibrosis transmembrane conductance regulator in human airway epithelial cells. J Biol Chem 285:27008\u201327018. https:\/\/doi.org\/10.1074\/jbc.M110.139881","journal-title":"J Biol Chem"},{"key":"5295_CR65","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.1191542","volume":"329","author":"T Okiyoneda","year":"2010","unstructured":"Okiyoneda T, Barri\u00e8re H, Bagd\u00e1ny M et al (2010) Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane. Science 329:805\u2013810. https:\/\/doi.org\/10.1126\/science.1191542","journal-title":"Science"},{"key":"5295_CR66","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3389\/fphar.2018.01100","volume":"9","author":"R Fukuda","year":"2018","unstructured":"Fukuda R, Okiyoneda T (2018) Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer. Front Pharmacol 9:1100. https:\/\/doi.org\/10.3389\/fphar.2018.01100","journal-title":"Front Pharmacol"},{"key":"5295_CR67","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.devcel.2018.02.001","volume":"44","author":"T Okiyoneda","year":"2018","unstructured":"Okiyoneda T, Veit G, Sakai R et al (2018) Chaperone-Independent Peripheral Quality Control of CFTR by RFFL E3 Ligase. Dev Cell 44:694-708.e7. https:\/\/doi.org\/10.1016\/j.devcel.2018.02.001","journal-title":"Dev Cell"},{"key":"5295_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.840649","author":"S Taniguchi","year":"2022","unstructured":"Taniguchi S, Ito Y, Kiritani H et al (2022) The Ubiquitin Ligase RNF34 Participates in the Peripheral Quality Control of CFTR (RNF34 Role in CFTR PeriQC). Front Mol Biosci. https:\/\/doi.org\/10.3389\/fmolb.2022.840649","journal-title":"Front Mol Biosci"},{"key":"5295_CR69","doi-asserted-by":"publisher","first-page":"115730","DOI":"10.1016\/j.bcp.2023.115730","volume":"215","author":"S Taniguchi","year":"2023","unstructured":"Taniguchi S, Ono Y, Doi Y et al (2023) Identification of \u03b1-Tocopherol succinate as an RFFL-substrate interaction inhibitor inducing peripheral CFTR stabilization and apoptosis. Biochem Pharmacol 215:115730. https:\/\/doi.org\/10.1016\/j.bcp.2023.115730","journal-title":"Biochem Pharmacol"},{"key":"5295_CR70","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.3390\/cells12232741","volume":"12","author":"Y Kamada","year":"2023","unstructured":"Kamada Y, Tateishi H, Nakayamada U et al (2023) UBE3C Facilitates the ER-Associated and Peripheral Degradation of Misfolded CFTR. Cells 12:2741. https:\/\/doi.org\/10.3390\/cells12232741","journal-title":"Cells"},{"key":"5295_CR71","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1091\/mbc.e09-03-0229","volume":"21","author":"J Cheng","year":"2010","unstructured":"Cheng J, Cebotaru V, Cebotaru L, Guggino WB (2010) Syntaxin 6 and CAL mediate the degradation of the cystic fibrosis transmembrane conductance regulator. Mol Biol Cell 21:1178\u20131187. https:\/\/doi.org\/10.1091\/mbc.e09-03-0229","journal-title":"Mol Biol Cell"},{"key":"5295_CR72","doi-asserted-by":"publisher","first-page":"e68001","DOI":"10.1371\/journal.pone.0068001","volume":"8","author":"J Cheng","year":"2013","unstructured":"Cheng J, Guggino W (2013) Ubiquitination and degradation of CFTR by the E3 ubiquitin ligase MARCH2 through its association with adaptor proteins CAL and STX6. PLoS ONE 8:e68001. https:\/\/doi.org\/10.1371\/journal.pone.0068001","journal-title":"PLoS ONE"},{"key":"5295_CR73","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1080\/15548627.2016.1192752","volume":"12","author":"D Xia","year":"2016","unstructured":"Xia D, Qu L, Li G et al (2016) MARCH2 regulates autophagy by promoting CFTR ubiquitination and degradation and PIK3CA-AKT-MTOR signaling. Autophagy 12:1614\u20131630. https:\/\/doi.org\/10.1080\/15548627.2016.1192752","journal-title":"Autophagy"},{"key":"5295_CR74","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1091\/mbc.E12-09-0678","volume":"24","author":"A Ahner","year":"2013","unstructured":"Ahner A, Gong X, Schmidt BZ et al (2013) Small heat shock proteins target mutant cystic fibrosis transmembrane conductance regulator for degradation via a small ubiquitin-like modifier-dependent pathway. Mol Biol Cell 24:74\u201384. https:\/\/doi.org\/10.1091\/mbc.E12-09-0678","journal-title":"Mol Biol Cell"},{"key":"5295_CR75","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/cr.2016.35","volume":"26","author":"MD Stewart","year":"2016","unstructured":"Stewart MD, Ritterhoff T, Klevit RE, Brzovic PS (2016) E2 enzymes: more than just middle men. Cell Res 26:423\u2013440. https:\/\/doi.org\/10.1038\/cr.2016.35","journal-title":"Cell Res"},{"key":"5295_CR76","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1042\/BST20220880","volume":"51","author":"AJ Middleton","year":"2023","unstructured":"Middleton AJ, Day CL (2023) From seeds to trees: how E2 enzymes grow ubiquitin chains. Biochem Soc Trans 51:353\u2013362. https:\/\/doi.org\/10.1042\/BST20220880","journal-title":"Biochem Soc Trans"},{"key":"5295_CR77","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/abbi.2001.2385","volume":"390","author":"GL Kiser","year":"2001","unstructured":"Kiser GL, Gentzsch M, Kloser AK et al (2001) Expression and Degradation of the Cystic Fibrosis Transmembrane Conductance Regulator in Saccharomyces cerevisiae. Arch Biochem Biophys 390:195\u2013205. https:\/\/doi.org\/10.1006\/abbi.2001.2385","journal-title":"Arch Biochem Biophys"},{"key":"5295_CR78","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1091\/mbc.12.5.1303","volume":"12","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Nijbroek G, Sullivan ML et al (2001) Hsp70 Molecular Chaperone Facilitates Endoplasmic Reticulum-associated Protein Degradation of Cystic Fibrosis Transmembrane Conductance Regulator in Yeast. MBoC 12:1303\u20131314. https:\/\/doi.org\/10.1091\/mbc.12.5.1303","journal-title":"MBoC"},{"key":"5295_CR79","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1242\/jcs.115.14.3007","volume":"115","author":"U Lenk","year":"2002","unstructured":"Lenk U, Yu H, Walter J et al (2002) A role for mammalian Ubc6 homologues in ER-associated protein degradation. J Cell Sci 115:3007\u20133014. https:\/\/doi.org\/10.1242\/jcs.115.14.3007","journal-title":"J Cell Sci"},{"key":"5295_CR80","doi-asserted-by":"publisher","first-page":"30408","DOI":"10.1074\/jbc.270.51.30408","volume":"270","author":"JP Jensen","year":"1995","unstructured":"Jensen JP, Bates PW, Yang M et al (1995) Identification of a family of closely related human ubiquitin conjugating enzymes. J Biol Chem 270:30408\u201330414. https:\/\/doi.org\/10.1074\/jbc.270.51.30408","journal-title":"J Biol Chem"},{"key":"5295_CR81","doi-asserted-by":"publisher","first-page":"e0163615","DOI":"10.1371\/journal.pone.0163615","volume":"11","author":"WJ Chung","year":"2016","unstructured":"Chung WJ, Goeckeler-Fried JL, Havasi V et al (2016) Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. PLoS ONE 11:e0163615. https:\/\/doi.org\/10.1371\/journal.pone.0163615","journal-title":"PLoS ONE"},{"key":"5295_CR82","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bcp.2011.05.012","volume":"82","author":"V Kapuria","year":"2011","unstructured":"Kapuria V, Peterson LF, Showalter HDH et al (2011) Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity. Biochem Pharmacol 82:341\u2013349. https:\/\/doi.org\/10.1016\/j.bcp.2011.05.012","journal-title":"Biochem Pharmacol"},{"key":"5295_CR83","doi-asserted-by":"publisher","first-page":"128243","DOI":"10.1016\/j.bmcl.2021.128243","volume":"48","author":"JL Goeckeler-Fried","year":"2021","unstructured":"Goeckeler-Fried JL, Aldrin Denny R, Joshi D et al (2021) Improved correction of F508del-CFTR biogenesis with a folding facilitator and an inhibitor of protein ubiquitination. Bioorg Med Chem Lett 48:128243. https:\/\/doi.org\/10.1016\/j.bmcl.2021.128243","journal-title":"Bioorg Med Chem Lett"},{"key":"5295_CR84","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00018-022-04215-3","volume":"79","author":"C Borgo","year":"2022","unstructured":"Borgo C, D\u2019Amore C, Capurro V et al (2022) Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor\/tezacaftor\/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants. Cell Mol Life Sci 79:192. https:\/\/doi.org\/10.1007\/s00018-022-04215-3","journal-title":"Cell Mol Life Sci"},{"key":"5295_CR85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13578-016-0127-1","volume":"6","author":"M He","year":"2016","unstructured":"He M, Zhou Z, Shah AA et al (2016) The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics. Cell Biosci 6:62. https:\/\/doi.org\/10.1186\/s13578-016-0127-1","journal-title":"Cell Biosci"},{"key":"5295_CR86","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/embor.2009.69","volume":"10","author":"GC Hassink","year":"2009","unstructured":"Hassink GC, Zhao B, Sompallae R et al (2009) The ER-resident ubiquitin-specific protease 19 participates in the UPR and rescues ERAD substrates. EMBO Rep 10:755\u2013761. https:\/\/doi.org\/10.1038\/embor.2009.69","journal-title":"EMBO Rep"},{"key":"5295_CR87","doi-asserted-by":"publisher","first-page":"18778","DOI":"10.1074\/jbc.M109.001685","volume":"284","author":"JM Bomberger","year":"2009","unstructured":"Bomberger JM, Barnaby RL, Stanton BA (2009) The deubiquitinating enzyme USP10 regulates the post-endocytic sorting of cystic fibrosis transmembrane conductance regulator in airway epithelial cells. J Biol Chem 284:18778\u201318789. https:\/\/doi.org\/10.1074\/jbc.M109.001685","journal-title":"J Biol Chem"},{"key":"5295_CR88","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4161\/chan.4.3.11223","volume":"4","author":"JM Bomberger","year":"2010","unstructured":"Bomberger JM, Barnaby RL, Stanton BA (2010) The deubiquitinating enzyme USP10 regulates the endocytic recycling of CFTR in airway epithelial cells. Channels (Austin) 4:150\u2013154. https:\/\/doi.org\/10.4161\/chan.4.3.11223","journal-title":"Channels (Austin)"},{"key":"5295_CR89","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3389\/fphar.2018.01464","volume":"9","author":"E Pesce","year":"2018","unstructured":"Pesce E, Sondo E, Ferrera L et al (2018) The Autophagy Inhibitor Spautin-1 Antagonizes Rescue of Mutant CFTR Through an Autophagy-Independent and USP13-Mediated Mechanism. Front Pharmacol 9:1464. https:\/\/doi.org\/10.3389\/fphar.2018.01464","journal-title":"Front Pharmacol"},{"key":"5295_CR90","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41589-022-00971-2","volume":"18","author":"NJ Henning","year":"2022","unstructured":"Henning NJ, Boike L, Spradlin JN et al (2022) Deubiquitinase-targeting chimeras for targeted protein stabilization. Nat Chem Biol 18:412\u2013421. https:\/\/doi.org\/10.1038\/s41589-022-00971-2","journal-title":"Nat Chem Biol"},{"key":"5295_CR91","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.3390\/ijms22105262","volume":"22","author":"V Capurro","year":"2021","unstructured":"Capurro V, Tomati V, Sondo E et al (2021) Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment. Int J Mol Sci 22:5262. https:\/\/doi.org\/10.3390\/ijms22105262","journal-title":"Int J Mol Sci"},{"key":"5295_CR92","doi-asserted-by":"publisher","first-page":"11972","DOI":"10.3390\/ijms222111972","volume":"22","author":"A Venturini","year":"2021","unstructured":"Venturini A, Borrelli A, Musante I et al (2021) Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene. Int J Mol Sci 22:11972. https:\/\/doi.org\/10.3390\/ijms222111972","journal-title":"Int J Mol Sci"},{"key":"5295_CR93","doi-asserted-by":"publisher","first-page":"246ra97","DOI":"10.1126\/scitranslmed.3008889","volume":"6","author":"G Veit","year":"2014","unstructured":"Veit G, Avramescu RG, Perdomo D et al (2014) Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression. Sci Transl Med 6:246ra97. https:\/\/doi.org\/10.1126\/scitranslmed.3008889","journal-title":"Sci Transl Med"},{"key":"5295_CR94","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jcf.2022.12.005","volume":"22","author":"V Tomati","year":"2023","unstructured":"Tomati V, Costa S, Capurro V et al (2023) Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation\u2019s stability and gating defects are dependent on cell background. J Cyst Fibros 22:525\u2013537. https:\/\/doi.org\/10.1016\/j.jcf.2022.12.005","journal-title":"J Cyst Fibros"},{"key":"5295_CR95","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4155\/fmc-2017-0009","volume":"9","author":"C Galdeano","year":"2017","unstructured":"Galdeano C (2017) Drugging the undruggable: targeting challenging E3 ligases for personalized medicine. Future Med Chem 9:347\u2013350. https:\/\/doi.org\/10.4155\/fmc-2017-0009","journal-title":"Future Med Chem"},{"key":"5295_CR96","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1091\/mbc.e08-09-0929","volume":"20","author":"DE Grove","year":"2009","unstructured":"Grove DE, Rosser MFN, Ren HY et al (2009) Mechanisms for rescue of correctable folding defects in CFTRDelta F508. Mol Biol Cell 20:4059\u20134069. https:\/\/doi.org\/10.1091\/mbc.e08-09-0929","journal-title":"Mol Biol Cell"},{"key":"5295_CR97","doi-asserted-by":"publisher","first-page":"e23094","DOI":"10.4161\/cib.23094","volume":"6","author":"KM Cihil","year":"2013","unstructured":"Cihil KM, Zimnik A, Swiatecka-Urban A (2013) c-Cbl reduces stability of rescued \u2206F508-CFTR in human airway epithelial cells: Implications for cystic fibrosis treatment. Commun Integr Biol 6:e23094. https:\/\/doi.org\/10.4161\/cib.23094","journal-title":"Commun Integr Biol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05295-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05295-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05295-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T15:02:46Z","timestamp":1718722966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05295-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5295"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05295-z","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"27 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"271"}}